Tempus AI, Inc. $TEM Shares Sold by Baillie Gifford & Co.

Key Points

• Baillie Gifford & Co. reduced its stake in Tempus AI by 9.8% in Q4, selling 950,999 shares and remaining the company's second-largest holder with 8,741,442 shares (about 4.91%) valued at roughly $516.2 million.
• Insiders have been net sellers recently: CEO Eric Lefkofsky sold 166,250 shares for $7.71 million, insiders sold 563,841 shares worth $32.26 million over the past 90 days, and insiders now own 26.27% of the company.
• Analyst coverage is mixed but leans positive—eight Buys, four Holds and one Sell—giving an average rating of Moderate Buy and an average price target of $75.92, while the stock trades near $42.94 with a 52-week range of $38.79–$104.32.

Baillie Gifford & Co. decreased its position in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 9.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,741,442 shares of the company's stock after selling 950,999 shares during the quarter. Baillie Gifford & Co. owned approximately 4.91% of Tempus AI worth $516,182,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of the stock. Victory Capital Management Inc. lifted its position in Tempus AI by 1.5% in the third quarter. Victory Capital Management Inc. now owns 11,078 shares of the company's stock valued at $894,000 after buying an additional 162 shares during the last quarter. Global Retirement Partners LLC lifted its position in Tempus AI by 29.5% in the third quarter. Global Retirement Partners LLC now owns 733 shares of the company's stock valued at $59,000 after buying an additional 167 shares during the last quarter. US Bancorp DE lifted its position in Tempus AI by 6.6% in the third quarter. US Bancorp DE now owns 2,848 shares of the company's stock valued at $230,000 after buying an additional 176 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Tempus AI by 0.7% in the second quarter. China Universal Asset Management Co. Ltd. now owns 33,757 shares of the company's stock valued at $2,145,000 after buying an additional 226 shares during the last quarter. Finally, SeaCrest Wealth Management LLC lifted its position in Tempus AI by 3.7% in the third quarter. SeaCrest Wealth Management LLC now owns 6,488 shares of the company's stock valued at $524,000 after buying an additional 229 shares during the last quarter. Institutional investors and hedge funds own 24.22% of the company's stock.

Wall Street Analyst Weigh In

TEM has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Tempus AI in a research report on Thursday, January 22nd. Needham & Company LLC reaffirmed a "buy" rating and issued a $75.00 target price on shares of Tempus AI in a research report on Wednesday, March 11th. Robert W. Baird initiated coverage on shares of Tempus AI in a research report on Tuesday, February 17th. They issued an "outperform" rating and a $59.00 target price on the stock. Mizuho initiated coverage on shares of Tempus AI in a research report on Thursday, February 19th. They issued an "outperform" rating and a $100.00 target price on the stock. Finally, Guggenheim reduced their price target on shares of Tempus AI from $95.00 to $60.00 and set a "buy" rating on the stock in a research report on Monday, March 30th. Eight investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $75.92.

Insider Activity

In related news, CAO Ryan M. Bartolucci sold 2,902 shares of the firm's stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $59.05, for a total value of $171,363.10. Following the sale, the chief accounting officer owned 41,159 shares of the company's stock, valued at $2,430,438.95. This trade represents a 6.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Eric P. Lefkofsky sold 166,250 shares of the firm's stock in a transaction that occurred on Thursday, March 26th. The shares were sold at an average price of $46.38, for a total transaction of $7,710,675.00. Following the completion of the sale, the chief executive officer directly owned 8,875,033 shares in the company, valued at approximately $411,624,030.54. This trade represents a 1.84% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 563,841 shares of company stock worth $32,258,311 over the last 90 days. Company insiders own 26.27% of the company's stock.

Tempus AI Price Performance

Shares of TEM opened at $42.94 on Monday. Tempus AI, Inc. has a fifty-two week low of $38.79 and a fifty-two week high of $104.32. The firm's 50 day moving average price is $51.10 and its 200 day moving average price is $66.77. The company has a market cap of $7.68 billion, a P/E ratio of -30.45 and a beta of 4.90. The company has a quick ratio of 3.00, a current ratio of 3.13 and a debt-to-equity ratio of 2.52.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

Want to see what other hedge funds are holding TEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tempus AI, Inc. (NASDAQ:TEM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.